Valuation: BICO Group AB

Market Cap 152.09Cr 15Cr 13Cr 13Cr 11Cr 22Cr 1.46TCr 22Cr 59Cr 742.16Cr 57Cr 56Cr 2.38TCr P/E 2026 *
-6.69x
P/E 2027 * -12x
Enterprise Value 145.19Cr 14Cr 13Cr 12Cr 11Cr 21Cr 1.39TCr 21Cr 56Cr 708.49Cr 54Cr 53Cr 2.28TCr EV / Sales 2026 *
0.9x
EV / Sales 2027 * 0.8x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 day-4.80%
1 month+3.86%
3 months+22.02%
6 months+12.86%
Current year-12.60%
1 month 2.15
Extreme 2.15
2.26
Current year 1.52
Extreme 1.522
2.31
1 year 1.52
Extreme 1.522
2.73
3 years 1.52
Extreme 1.522
6.9
5 years 1.52
Extreme 1.522
60.45
10 years 0
Extreme 0
100
Manager TitleAgeSince
Chief Executive Officer 51 01/09/2026
Director of Finance/CFO 56 01/03/2026
Chief Operating Officer - 07/01/2026
Director TitleAgeSince
Director/Board Member 71 18/12/2019
Director/Board Member 37 01/03/2015
Director/Board Member - 07/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-4.80%-.--% - - 15Cr
-3.34%-3.81%+22.95%+28.91% 25TCr
-4.42%-5.37%-0.53%-14.65% 16TCr
-1.33%+0.43%-8.40%+37.27% 14TCr
-0.96%-3.25%-54.90%-18.12% 6.33TCr
-1.31%-0.63%+11.64%+22.96% 4.98TCr
-3.27%-3.56%+20.28%+49.06% 4.86TCr
-0.95%+1.10%-18.27%-21.65% 4.8TCr
-1.23%+2.58%-3.86%+38.57% 4.62TCr
-3.15%-1.11%+33.06%+55.18% 4.32TCr
Average -2.48%+0.29%+0.22%+19.73% 9.42TCr
Weighted average by Cap. -2.64%+0.45%+3.42%+18.63%

Financials

2026 *2027 *
Net sales 162.2Cr 16Cr 14Cr 13Cr 12Cr 23Cr 1.55TCr 23Cr 63Cr 791.5Cr 61Cr 59Cr 2.54TCr 168.55Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.61TCr 24Cr 65Cr 822.48Cr 63Cr 62Cr 2.64TCr
Net income -23Cr -2.26Cr -2.01Cr -1.88Cr -1.71Cr -3.22Cr -217.5Cr -3.26Cr -8.79Cr -110.77Cr -8.48Cr -8.3Cr -355.79Cr -13Cr -1.25Cr -1.11Cr -1.04Cr -94.91L -1.79Cr -120.73Cr -1.81Cr -4.88Cr -61Cr -4.71Cr -4.61Cr -197.48Cr
Net Debt -6.9Cr -68.67L -60.99L -57.04L -51.98L -97.85L -66Cr -99.2L -2.67Cr -34Cr -2.58Cr -2.52Cr -108.15Cr -17Cr -1.65Cr -1.47Cr -1.37Cr -1.25Cr -2.35Cr -159.05Cr -2.39Cr -6.43Cr -81Cr -6.2Cr -6.07Cr -260.18Cr
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
554
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
21.55SEK
Average target price
29.00SEK
Spread / Average Target
+34.57%

Quarterly revenue - Rate of surprise